Rapport therapeutics presents data demonstrating consistent association between decreases in rns measured long episodes and meaningful reductions in clinical seizures

A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies change in long episode frequency is the primary endpoint for rapport's ongoing phase 2a proof-of-concept trial in focal epilepsy, with topline data expected in mid-2025 data from additional studies, including preclinical seizure data and phase 1 pharmacokinetic and safety trial results, support the potential of rap-219 as a transformational treatment for patients with focal epilepsy boston and los angeles, dec. 06, 2024 (globe newswire) -- rapport therapeutics, inc. (nasdaq: rapp), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (cns) disorders, presents novel findings on the association between a seizure biomarker used in the company's proof-of-concept trial for rap-219 and clinical seizures. the analysis demonstrated a linear relationship between changes in long episode (le) frequency and clinical seizure frequency and identified the benchmark to predict clinically meaningful seizure reduction.
RAPP Ratings Summary
RAPP Quant Ranking